Claims for Patent: 7,445,775

Summary for Patent: 7,445,775

Title:	Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
Abstract:	Vectors for the expression in yeast of mammalian plasminogen derivatives such as microplasminogen and miniplasminogen are presented. Methods for expression of these proteins in a methylotrophic yeast expression system are disclosed as well as the activation and stabilisation of the recombinant proteins. The proteins of this invention are used In the treatment of focal cerebral ischemic infarction and other thrombotic diseases.
Inventor(s):	Collen; Desire Jose (London, GB), Nagai; Nubuo (Leuven, BE), Laroche; Yves (Brussel, BE)
Assignee:	Thromb-X nv (Leuven, BE)
Application Number:	10/450,976
Patent Claims:	1. A yeast cell expressing microplasminogen encoded by a mammalian nucleotide sequence, wherein the amino acid sequence of said microplasminogen consists of the amino acid sequence of SEQ ID NO: 4. 2. The yeast cell according to claim 1, wherein said mammalian nucleotide sequence is the nucleotide sequence of SEQ ID NO: 3. 3. The yeast cell according to claim 1, wherein said mammalian nucleotide sequence is under the control of an inducible promoter. 4. The yeast cell according to claim 1, said yeast cell belonging to the group of the methylotrophic yeasts. 5. The yeast cell according to claim 4, wherein said yeast is selected from the group consisting of the Hansenula, Pichia, Candida and Torulopsis genera. 6. The yeast cell according to claim 4, belonging to the Pichia pastoris species. 7. The yeast cell according to claim 1, wherein said mammalian nucleotide sequence is integrated into the genome of said yeast cell. 8. The yeast cell according to claim 1, wherein said yeast cell is the deposited cell line with accession number MUCL43676. 9. The yeast cell according to claim 1, expressing said microplasminogen at a level of at least about 100 mg/litre. 10. The yeast cell according to claim 1, wherein said mammalian nucleotide sequence is fused to a nucleotide sequence encoding a secretion signal. 11. A yeast cell expressing microplasminogen, wherein the amino acid sequence of said microplasminogen consists of the amino acid sequence of SEQ ID NO: 4. 12. A method of producing activated microplasmin, said method comprising the steps of: (a) providing a yeast cell that is transformed with a nucleotide sequence encoding a microplasminogen amino acid sequence consisting of the amino acid sequence of SEQ ID NO: 4; (b) culturing said yeast cell under conditions such that a microplasminogen consisting of said amino acid sequence is expressed; and (c) activating said microplasminogen by means of a plasminogen activator. 13. The method according to claim 12, wherein said plasminogen activator is staphylokinase. 14. The method according to claim 12, further comprising the step of stabilizing the expressed and activated microplasmin by means of a stabilizing agent or medium. 15. The method according to claim 14, wherein said stabilizing agent comprises an amino-acid selected from the group consisting of lysine, 6-amino hexanoic acid and tranexamic acid. 16. The method according to claim 14, wherein said stabilizing medium is an acid solution or an acid buffer. 17. The method according to claim 16, wherein said stabilizing medium is a citrate buffer with a pH of about 3.1. 18. The method according to claim 14, further comprising the step of drying the expressed, activated and stabilized microplasmin. 19. A recombinant mammalian protein obtained by the method according to claim 12. 20. The method according to claim 12, wherein said yeast cell is transformed with the nucleotide sequence of SEQ ID NO: 3 and a high expression Pichia strain of microplasminogen is selected. 21. The method according to claim 12, which optionally comprises the step of purifying said expressed microplasminogen obtained in step (b) by one or more purification methods. 22. The method according to claim 12 wherein said yeast cell is the deposited strain with accession number MUCL43676. 23. The method according to claim 12, wherein said microplasminogen is expressed at a level of about 100 mg/litre. 24. An isolated nucleotide sequence encoding a fusion protein of microplasminogen and a secretion signal sequence, wherein the amino acid sequence of said microplasminogen consists of the amino acid sequence of SEQ ID NO: 4. 25. The isolated nucleotide sequence of claim 24, said nucleotide sequence comprising the nucleotide sequence of SEQ ID NO: 3. 26. An isolated cell containing the nucleic acid molecule of claim 24. 27. An isolated vector containing the nucleic acid molecule of claim 24. 28. An isolated cell containing the vector of claim 27. 29. A purified microplasminogen, wherein the amino acid sequence of said microplasminogen consists of the amino acid sequence of SEQ ID NO: 4. 30. An isolated cell producing the microplasminogen of claim 29. 31. A pharmaceutical composition comprising microplasminogen, wherein the amino acid sequence of said microplasminogen consists of the amino acid sequence of SEQ ID NO: 4. 32. The pharmaceutical composition of claim 31, further comprising a pharmaceutically-acceptable carrier.

Details for Patent 7,445,775

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	February 22, 2017	7,445,775	2020-12-21
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	October 17, 2012	7,445,775	2020-12-21

International Patent Family for US Patent 7,445,775

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	0250290
United States of America	2004071676
Portugal	1343903